Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

George Abercrombie joins Ziopharm's board

This article was originally published in Scrip

Executive Summary

Ziopharm Oncology (US) has appointed George Abercrombie to its board of directors. He will also serve as a member of the board’s compensation committee, as well as the nominating and corporate governance committee. The company has also elected Dr Murray Brennan chairman of the board. Mr Abercrombie most recently served as president and CEO of Roche North America and has more than 30 years' experience in the pharmaceutical industry. Before joining Roche in 2001, Mr Abercrombie was senior vice-president of commercial operations at Glaxo Wellcome.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC008326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel